NCT05059262 2026-03-20
MOTION
Deciphera Pharmaceuticals, LLC
Phase 3 Active not recruiting
Clinical Trials
10 trialsNCT04703322 2026-03-04
A Study of Pexidartinib in Tenosynovial Giant Cell Tumor in Japan
Daiichi Sankyo
Phase 2 Active not recruiting
NCT01207492 2026-02-20
Nilotinib in Patients With Relapsed or Metastatic Pigmented Villonodular Synovitis/Tenosynovial Giant Cell Tumor/Diffuse-Type Giant Cell Tumor
Dana-Farber Cancer Institute
Phase 2 Completed
NCT04731675 2024-06-27
An Open-Label Study of Intra-articular AMB-05X Injections in Subjects With Tenosynovial Giant Cell Tumor of the Knee
AmMax Bio, Inc.
Phase 2 Completed
NCT04938180 2024-05-24
A Phase 2 Study of Intravenous AMB-05X in Tenosynovial Giant Cell Tumor Patients
AmMax Bio, Inc.
Phase 2 Terminated
NCT02948088 2023-10-31
TOP
Daiichi Sankyo
Completed
NCT02371369 2022-05-11
ENLIVEN
Daiichi Sankyo
Phase 3 Completed
NCT02471716 2021-08-31
FPA008-002
Five Prime Therapeutics, Inc.
Phase 1/2 Completed
NCT03291288 2021-05-14
Effect of Pexidartinib on the Way the Body Processes CYP3A4 and CYP2C9 Substrates (Pharmacokinetics)
Daiichi Sankyo
Phase 1 Completed
NCT01643850 2021-01-05
MCS110 in Patients With Pigmented Villonodular Synovitis (PVNS)
Novartis
Phase 2 Completed